• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

October 13, 2011 - Amgen

http://www.amgen.com

Gregory Friberg, MD - Executive Medical Director, Medical Sciences Oncology Early Development
Ada Braun, MD - Executive Medical Director, Global Development
David Reese, MD - VP Medical Sciences
Darrin Beaupre, MD - Medical Director, Medical Sciences

Presentation on:

  • Amgen Early Development Pipeline


October 4, 2011 - Methylgene

http://www.methylgene.com

Jeffrey Besterman, PhD -Executive Vice President,  Research and Development & Chief Scientific Officer

Presentation on:

  • Mocetinostat (MGCD0103)
  • MGCD265 - met-kinase inhibitor


June 1, 2011 - Antisense Pharma

http://www.antisense.com

Hubert Heinrichs - Chief Medical Officer
Piotr Jachimczak - Senior Scientific Advisor

Presentation on:

  • Trabidersen (AP12009)
  • AP11014 - TGF-beta 1 expression inhibitor


May 17 - Tracon Pharma

http://www.traconpharma.com

Charles Theuer, MD, PhD - President and CEO

Presentation on:

  • TRC093 - recombinant humanized IgG1 MAb
  • TRC105 - Human chimeric MAb that bind CD105 


May 9, 2011 - Intezyne

http://www.intezyne.com/

1:1 meetings only


March 24, 2011 - Cerulean Pharmaceuticals

http://www.ceruleanrx.com/

John Ryan, MD, PhD - Acting Chief Medical Officer
Scott Eliasof, PhD - Vice President of Research

Presentation on:

  • CRLX101 - Novel Camptothecin Nanopharmaceutical


February 15, 2011 - Abbott

http://www.abbott.com

Rod Humerickhouse - Global Project Head

Presentation on:

  • Abbott Pipeline


January 18, 2011 - Acceleron

http://www.acceleronpharma.com/

Matthew Sherman - Chief Medical Officer
John Oram - Program Management
Jonathan Yu - Business and Market Development

Presentation on:

  • ACE-041 - Novel angiogenesis inhibitor targeting ALK1